<DOC>
	<DOCNO>NCT01984346</DOCNO>
	<brief_summary>This multi-center , open label , randomize pivotal study evaluate safety efficacy EPi-Sense-AF Guided Coagulation System treatment persistent AF patient , refractory intolerant least one Class I and/or III Anti Arrhythmic Drug ( AAD ) .</brief_summary>
	<brief_title>CONVERGE - Epi/Endo Ablation For Treatment Persistent Atrial Fibrillation ( AF )</brief_title>
	<detailed_description>The objective randomize pivotal study evaluate safety efficacy AtriCure EPi-Sense®-AF Guided Coagulation System VisiTrax® treatment symptomatic persistent Atrial Fibrillation ( AF ) patient , refractory intolerant least one Class I Class III anti-arrhythmic drug ( AAD ) . 153 subject 27 US 3 OUS site . Randomized 2:1 . The primary efficacy endpoint success failure AF/AT/AFL free absent class I III AADs except previously fail intolerant class I III AAD increase dosage follow 3-month blanking period 12-month post procedure follow-up visit . The primary safety endpoint incidence major adverse event ( MAEs ) list protocol subject undergoing convergent procedure procedural 30-day post procedure time period .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Age &gt; 18 year ; &lt; 80 year Left atrium &lt; 6.0 cm Refractory intolerant one AAD ( class I and/or III ) Documentation persistent AF Provided write informed consent Patients require concomitant surgery Left ventricular ejection fraction &lt; 40 % Pregnant planning become pregnant study Comorbid medical condition limit one year life expectancy Previous cardiac surgery History pericarditis Previous cerebrovascular accident ( CVA ) , exclude fully resolve transient Ischemic attack ( TIA ) Patients active infection sepsis Patients esophageal ulcer stricture varix Patients renal dysfunction dialysis Patients contraindicate anticoagulant Patients treat ventricular arrhythmia Patients previous leave atrial catheter ablation AF Patients exist Implantable CardioverterDefibrillator ( ICDs ) Current participation another clinical investigation medical device drug , recent participation study within 30 day prior study enrollment Not competent legally represent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Convergent Procedure</keyword>
	<keyword>Combined Epicardial/ Endocardial Ablation</keyword>
	<keyword>Hybrid Procedure</keyword>
	<keyword>Radiofrequency Ablation</keyword>
	<keyword>Arrhythmia</keyword>
	<keyword>RF Ablation</keyword>
</DOC>